CN101199847A - At1受体拮抗剂/利尿剂/叶酸联用的药物组合物及其用途 - Google Patents
At1受体拮抗剂/利尿剂/叶酸联用的药物组合物及其用途 Download PDFInfo
- Publication number
- CN101199847A CN101199847A CNA2007101657754A CN200710165775A CN101199847A CN 101199847 A CN101199847 A CN 101199847A CN A2007101657754 A CNA2007101657754 A CN A2007101657754A CN 200710165775 A CN200710165775 A CN 200710165775A CN 101199847 A CN101199847 A CN 101199847A
- Authority
- CN
- China
- Prior art keywords
- group
- hydrochlorothiazide
- hypertension
- folic acid
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 161
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 91
- 239000011724 folic acid Substances 0.000 title claims abstract description 91
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 239000002934 diuretic Substances 0.000 title claims abstract description 41
- 230000001882 diuretic effect Effects 0.000 title claims abstract description 41
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title claims abstract description 23
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title description 15
- 229940079593 drug Drugs 0.000 title description 14
- 150000001875 compounds Chemical class 0.000 title description 10
- 230000008878 coupling Effects 0.000 title description 5
- 238000010168 coupling process Methods 0.000 title description 5
- 238000005859 coupling reaction Methods 0.000 title description 5
- 229940014144 folate Drugs 0.000 title description 2
- 206010020772 Hypertension Diseases 0.000 claims abstract description 108
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 72
- 229960000304 folic acid Drugs 0.000 claims abstract description 72
- -1 folic acid compound Chemical class 0.000 claims abstract description 19
- 229940064302 folacin Drugs 0.000 claims abstract description 17
- 230000008816 organ damage Effects 0.000 claims abstract description 13
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims abstract description 8
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical compound [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 claims description 33
- 208000006011 Stroke Diseases 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 32
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 31
- 239000005480 Olmesartan Substances 0.000 claims description 31
- 229960005117 olmesartan Drugs 0.000 claims description 31
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 30
- 230000001631 hypertensive effect Effects 0.000 claims description 30
- 229940047417 levoleucovorin calcium Drugs 0.000 claims description 30
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 30
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 29
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims description 28
- 229960004569 indapamide Drugs 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 24
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 22
- 125000003929 folic acid group Chemical group 0.000 claims description 22
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 18
- 229960002198 irbesartan Drugs 0.000 claims description 18
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 16
- 239000003826 tablet Substances 0.000 claims description 11
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 9
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 9
- 229960000932 candesartan Drugs 0.000 claims description 9
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 8
- 235000008207 calcium folinate Nutrition 0.000 claims description 8
- 239000011687 calcium folinate Substances 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- 229960005187 telmisartan Drugs 0.000 claims description 8
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 201000009925 nephrosclerosis Diseases 0.000 claims description 6
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 229960004563 eprosartan Drugs 0.000 claims description 3
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 230000000505 pernicious effect Effects 0.000 claims description 3
- 230000002207 retinal effect Effects 0.000 claims description 3
- 229960002256 spironolactone Drugs 0.000 claims description 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 3
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
- 229960001208 eplerenone Drugs 0.000 claims description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004699 valsartan Drugs 0.000 claims description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 239000000890 drug combination Substances 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000007211 cardiovascular event Effects 0.000 abstract 1
- 230000007213 cerebrovascular event Effects 0.000 abstract 1
- 238000001647 drug administration Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 121
- OZCVMXDGSSXWFT-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OZCVMXDGSSXWFT-UHFFFAOYSA-N 0.000 description 65
- 229940097420 Diuretic Drugs 0.000 description 36
- 230000036772 blood pressure Effects 0.000 description 36
- 102000008186 Collagen Human genes 0.000 description 35
- 108010035532 Collagen Proteins 0.000 description 35
- 229920001436 collagen Polymers 0.000 description 34
- 210000002700 urine Anatomy 0.000 description 32
- CWFIALYLRRPPJU-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 CWFIALYLRRPPJU-UHFFFAOYSA-N 0.000 description 30
- 230000002107 myocardial effect Effects 0.000 description 29
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 24
- 210000004165 myocardium Anatomy 0.000 description 24
- 229940114026 candesartan / hydrochlorothiazide Drugs 0.000 description 21
- 229920001756 Polyvinyl chloride acetate Polymers 0.000 description 20
- 230000002269 spontaneous effect Effects 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 229920002472 Starch Polymers 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 235000019698 starch Nutrition 0.000 description 18
- 239000008107 starch Substances 0.000 description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 15
- 239000008108 microcrystalline cellulose Substances 0.000 description 15
- 210000003975 mesenteric artery Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 229910052708 sodium Inorganic materials 0.000 description 13
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 12
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 12
- 102000002045 Endothelin Human genes 0.000 description 12
- 108050009340 Endothelin Proteins 0.000 description 12
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 12
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 12
- 150000004102 olmesartan derivatives Chemical group 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 229940121792 Thiazide diuretic Drugs 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 239000003451 thiazide diuretic agent Substances 0.000 description 11
- 206010016654 Fibrosis Diseases 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000004761 fibrosis Effects 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 description 9
- 108010012715 Superoxide dismutase Proteins 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 229940082195 hydrochlorothiazide 12.5 mg Drugs 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 8
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 8
- 229960002591 hydroxyproline Drugs 0.000 description 8
- 230000003907 kidney function Effects 0.000 description 8
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 238000004043 dyeing Methods 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 210000000653 nervous system Anatomy 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 239000002220 antihypertensive agent Substances 0.000 description 6
- 229940127088 antihypertensive drug Drugs 0.000 description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- 230000003387 muscular Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000001363 mesenteric artery superior Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940101539 telmisartan 40 mg Drugs 0.000 description 4
- 210000004231 tunica media Anatomy 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000034777 Vitreous degeneration Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002567 autonomic effect Effects 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960003624 creatine Drugs 0.000 description 3
- 239000006046 creatine Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229940083565 folic acid 0.8 mg Drugs 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 201000011288 vitreous syneresis Diseases 0.000 description 3
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 101100008049 Caenorhabditis elegans cut-5 gene Proteins 0.000 description 2
- 206010015856 Extrasystoles Diseases 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960002274 atenolol Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940083626 folic acid 0.4 mg Drugs 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940082063 indapamide 2.5 mg Drugs 0.000 description 2
- 229940082094 irbesartan 150 mg Drugs 0.000 description 2
- 229940008678 levoleucovorin Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- UIYUUEDFAMZISF-FTBISJDPSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NNN=N1 UIYUUEDFAMZISF-FTBISJDPSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940036630 folic acid 0.2 mg Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical group C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- XRKMYXDEMOEFBN-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol;6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound [K+].C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N-]N=NN=2)C=C1 XRKMYXDEMOEFBN-UHFFFAOYSA-N 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001154 skull base Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229940097015 spironolactone 50 mg Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229940124629 β-receptor antagonist Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
合用类型 | 合用剂量配比,mg* |
血管紧张素II受体拮抗剂和利尿剂 | 坎地沙坦/氢氯噻嗪(16/12.5,32/12.5,32/25) |
甲磺酸依普沙坦/氢氯噻嗪(600/12.5,600/25) | |
厄贝沙坦/氢氯噻嗪(75/12.5,150/12.5,300/12.5,300/25) | |
氯沙坦/氢氯噻嗪(50/12.5,300/12.5,300/25) | |
替米沙坦/氢氯噻嗪(40/12.5,80/12.5,80/25) | |
缬沙坦/氢氯噻嗪(80/12.5,160/12.5,160/25) | |
奥美沙坦/氢氯噻嗪(20/12.5,40/12.5,40/25) | |
*可得到多种固定剂量的复方药物。每种药物的剂量均为mg |
组别 | 剂量(mg/kg) | 数量(n) | 降压幅度(mmHg) | NO(mmol/L) | ET(pg/ml) | SOD(kU/L) | MDA(umol/L) |
正常组 | - | 18 | -1.6±3.0 | 84.8±16.2 | 73.5±16.5 | 164.8±40.2 | 1.05±0.22 |
高血压 | - | 17 | -14.5±6.2** | 43.2±10.3** | 132.8±30.2** | 78.6±23.1** | 3.68±0.84** |
替米沙坦/氢氯噻嗪+叶酸 | 4+1.25+0.04 | 19 | 33.6±10.6▲▲ | 68.2±13.5▲▲ | 85.6±13.7▲▲★ | 125.7±27.6▲▲★★ | 1.95±0.39▲▲★ |
替米沙坦/氢氯噻嗪+叶酸 | 4+1.25+0.08 | 17 | 35.2±12.0▲▲★ | 74.5±13.2▲▲★ | 90.2±17.4▲▲ | 135.2±19.4▲▲★★ | 1.53±0.28▲▲★★ |
替米沙坦/氢氯噻嗪 | 4+1.25 | 17 | 24.3±10.2▲▲ | 59.2±16.8▲ | 102.6±20.2▲▲ | 96.6±18.3▲ | 2.39±0.43▲▲ |
叶酸 | 0.08 | 16 | -8.5±4.9▲ | 63.0±26.6▲ | 109.8±14.9▲▲ | 106.2±20.3▲▲ | 2.07±0.82▲▲ |
组别 | 剂量(mg/kg) | 动物数 | 尿蛋白(mg) | 24hα1-微球蛋白(μg) | Ccr(ml/min) | BUN(mmol/L) |
正常组 | - | 18 | 5.3±3.2 | 21.2±8.2 | 0.355±0.116 | 7.34±1.12 |
高血压组 | - | 17 | 30.6±9.2** | 89.3±23.1** | 0.226±0.060** | 9.62±2.13** |
替米沙坦+氢氯噻嗪+叶酸 | 4+1.25+0.04 | 19 | 18.3±4.5▲▲★ | 49.8±12.3▲▲★★ | 0.314±0.044▲▲ | 7.89±1.16▲▲ |
替米沙坦+氢氯噻嗪+叶酸 | 4+1.25+0.08 | 17 | 17.1±3.4▲▲★★ | 52.4±12.3▲▲★ | 0.326±0.037▲▲★ | 7.21±0.76▲▲ |
替米沙坦+氢氯噻嗪 | 4+1.25 | 17 | 22.4±5.2▲▲ | 66.6±16.3▲▲ | 0.286±0.046▲▲ | 7.93±0.96▲▲ |
叶酸 | 0.08 | 16 | 27.4±9.0 | 85.6±31.4 | 0.216±0.055 | 8.56±1.25 |
组别 | 剂量(mg/kg) | 动物数 | 左心室重量(mg) | 室重指数(mg/g) | 心肌胶原含量(mg/g) |
正常组 | - | 18 | 800.2±127.4 | 1.91±0.15 | 1.65±0.26 |
高血压组 | - | 17 | 921.3±145.2** | 3.07±0.31** | 3.60±0.57** |
替米沙坦+氢氯噻嗪+叶酸 | 4+1.25+0.04 | 19 | 743.8±136.7▲▲ | 2.39±0.34▲▲ | 2.76±0.21▲▲★ |
替米沙坦+氢氯噻嗪+叶酸 | 4+1.25+0.08 | 17 | 738.6±97.3▲▲ | 2.36±0.21▲▲ | 2.68±0.41▲▲★ |
替米沙坦+氢氯噻嗪 | 4+1.25 | 17 | 795.3±125.4▲▲ | 2.55±0.28▲▲ | 3.06±0.36▲▲ |
叶酸 | 0.08 | 16 | 905.2±178.6 | 2.98±0.30 | 3.32±0.48 |
组别 | 剂量(mg/kg) | 动物数 | 心肌细胞面积(μm2) | 细胞长径(μm) | 细胞短径(μm) |
正常组 | - | 18 | 70.8±10.8 | 11.66±2.31 | 7.87±1.07 |
高血压组 | - | 17 | 116.8±20.4** | 16.05±2.13** | 10.32±1.34** |
替米沙坦+氢氯噻嗪+叶酸 | 4+1.25+0.04 | 19 | 81.9±10.5▲▲★ | 13.0±1.34▲▲ | 8.10±1.79▲▲ |
替米沙坦+氢氯噻嗪+叶酸 | 4+1.25+0.08 | 17 | 83.6±9.8▲▲★ | 12.50±2.83▲▲ | 9.14±0.85▲ |
替米沙坦+氢氯噻嗪 | 4+1.25 | 17 | 91.5±7.4▲▲ | 14.0±1.14▲▲ | 8.78±1.09▲▲ |
叶酸 | 0.08 | 16 | 111.6±8.8 | 15.16±2.30 | 10.11±1.35 |
组别 | 剂量(mg/kg) | 动物数 | CVF(%) | PVCA(%) |
WKY组 | - | 18 | 1.88±0.45 | 1.16±0.83 |
高血压组 | - | 17 | 5.31±1.18** | 4.85±1.17** |
替米沙坦+氢氯噻嗪+叶酸 | 4+1.25+0.04 | 19 | 3.44±0.33▲▲★ | 3.09±0.30▲▲★ |
替米沙坦+氢氯噻嗪+叶酸 | 4+1.25+0.08 | 17 | 3.53±0.42▲▲★ | 3.14±0.36▲▲★ |
替米沙坦+氢氯噻嗪 | 4+1.25 | 17 | 3.93±0.36▲▲ | 3.60±0.52▲▲ |
叶酸 | 0.08 | 16 | 5.14±1.08 | 3.90±0.79▲ |
组别 | 剂量(mp/kg) | 动物数 | 中膜厚度(μm) | 血管内径(μm) | 中膜厚度/内径(%) |
正常组 | - | 18 | 24.3±6.5 | 226.9±26.6 | 11.2±3.6 |
高血压组 | - | 17 | 46.4±8.7** | 178.7±21.1** | 26.4±5.4** |
替米沙坦+氢氯噻嗪+叶酸 | 4+1.25+0.04 | 19 | 31.5±4.7▲▲★★ | 217.8±22.6▲▲ | 14.1±3.7▲▲★★ |
替米沙坦+氢氯噻嗪+叶酸 | 4+1.25+0.08 | 17 | 33.4±4.2▲▲ | 223.5±16.7▲▲ | 14.7±3.1▲▲★★ |
替米沙坦+氢氯噻嗪 | 4+1.25 | 17 | 37.5±5.4▲▲ | 205.4±20.9▲▲ | 18.6±3.4▲▲ |
叶酸 | 0.08 | 16 | 42.8±9.8 | 185.5±17.5 | 23.5±4.8 |
组别 | 剂量(mg/kg) | 动物数 | 0级 | 1级 | 2级 | 3级 | 4级 |
正常组 | - | 28 | 28 | 0 | 0 | 0 | 0 |
模型组** | - | 25 | 7 | 1 | 5 | 6 | 6 |
坎地沙坦/氢氯噻嗪▲ | 1.6+1.25 | 27 | 11 | 5 | 6 | 3 | 2 |
坎地沙坦/氢氯噻嗪+叶酸▲▲★ | 1.6+1.25+0.08 | 27 | 16 | 7 | 3 | 0 | 1 |
组别 | 剂量(mg/kg) | 动物数 | 0级 | 1级 | 2级 | 3级 | 4级 |
正常组 | - | 28 | 28 | 0 | 0 | 0 | 0 |
模型组** | - | 21 | 5 | 2 | 2 | 5 | 7 |
坎地沙坦/氢氯噻嗪▲ | 1.6+1.25 | 23 | 10 | 2 | 3 | 5 | 3 |
坎地沙坦/氢氯噻嗪+叶酸▲▲★ | 1.6+1.25+0.08 | 23 | 15 | 4 | 1 | 1 | 2 |
组别 | 剂量(mg/kg) | 脑卒中发生数/实际观察数 | 病理组织学观察脑卒中发生数/实际观察数 |
正常组 | - | 0/30 | 0/29 |
模型组** | - | 18/28** | 24/29** |
坎地沙坦/氢氯噻嗪 | 1.6+1.25 | 12/30▲ | 17/29▲ |
坎地沙坦/氢氯噻嗪+叶酸 | 1.6+1.25+0.08 | 7/29▲▲ | 9/28▲▲★ |
组别 | 剂量(mg/kg) | 动物数 | 中膜厚度(μm) | 管腔内径(μm) | 中膜厚度/管腔内径(%) |
对照组 | - | 28 | 14.6±4.2 | 84.2±14.6 | 17.6±3.6 |
模型组 | - | 18 | 46.1±7.9** | 60.6±8.4** | 78.2±8.4** |
坎地沙坦/氢氯噻嗪 | 1.6+1.25 | 20 | 33.2±5.2▲▲ | 74.6±9.8▲▲ | 46.4±5.8▲▲ |
坎地沙坦/氢氯噻嗪+叶酸 | 1.6+1.25+0.08 | 22 | 28.7±4.8▲▲ | 78.6±10.1▲▲ | 37.2±6.1▲▲★★ |
组别 | 剂量(mg/kg) | 给药前血压(n) | 8周血压(n) | 16周血压(n) | 20周血压(n) |
正常组 | - | 109.6±12.5(20) | 112.6±15.3(20) | 122.4±16.4(20) | 130.3±18.9(19) |
模型组 | - | 174.6±16.3**(20) | 180.6±18.7**(18) | 182.5±19.6**(18) | 188.2±20.4**(16) |
奥美沙坦/吲达帕胺+左旋亚叶酸钙 | 2+0.25+0.02 | 177.4±16.8(20) | 144.3±20.2▲▲(19) | 142.5±17.5▲▲(18) | 144.2±20.4▲▲(18) |
2+0.25+0.04 | 176.2±15.4(20) | 140.1±20.3▲▲(20) | 139.5±20.3▲▲(20) | 143.6±24.7▲▲(19) | |
奥美沙坦/吲达帕胺 | 2+0.25 | 176.2±19.5(20) | 144.5±13.4▲▲(20) | 147.6±14.7▲▲(18) | 152.2±14.5▲▲(17) |
左旋亚叶酸钙 | 0.04 | 174.6±21.2(20) | 175.6±22.8(19) | 170.3±23.6(18) | 178.8±21.9(17) |
组别 | 剂量(mg/kg) | N | 尿蛋白(mg/24h) | 24hα1-微球蛋白(μg) | Ccr(ml/min) |
正常组 | - | 19 | 1.33±0.22 | 9.4±2.1 | 0.393±0.064 |
模型组 | - | 16 | 6.41±1.56** | 54.7±12.6** | 0.211±0.032** |
奥美沙坦/吲达帕胺+左旋亚叶酸钙 | 2+0.25+0.02 | 18 | 3.67±0.67▲▲★ | 35.6±5.9▲▲★ | 0.279±0.040▲▲ |
2+0.25+0.04 | 19 | 3.38±0.82▲▲★★ | 32.4±6.9▲▲★★ | 0.309±0.036▲▲★ | |
奥美沙坦/吲达帕胺 | 2+0.25 | 17 | 4.46±0.93▲▲ | 41.7±8.4▲▲ | 0.265±0.041▲▲ |
左旋亚叶酸钙 | 0.04 | 17 | 6.11±1.83 | 56.2±15.4 | 0.401±0.051 |
组别 | 剂量(mg/kg) | N | 胶原蛋白(mg/g) | CVF(%) | PVCA(%) |
正常组 | - | 19 | 0.93±0.26 | 1.21±0.32 | 0.75±0.23 |
模型组 | - | 16 | 4.45±1.02** | 4.33±0.76** | 3.15±0.45** |
奥美沙坦/吲达帕胺+左旋亚叶酸钙 | 2+0.25+0.02 | 18 | 3.23±0.33▲★ | 2.91±0.43▲▲★ | 2.36±0.29▲▲ |
2+0.25+0.04 | 19 | 3.16±0.46▲▲★ | 2.76±0.57▲▲★★ | 2.15±0.37▲▲★★ | |
奥美沙坦/吲达帕胺 | 2+0.25 | 17 | 3.71±0.54▲▲ | 3.45±0.56▲▲ | 2.62±0.42▲▲ |
左旋亚叶酸钙 | 0.04 | 17 | 4.33±0.81 | 4.09±0.94 | 2.85±0.42▲ |
组别 | 剂量(mg/kg) | N | 中膜厚度(um) | 血管内径(μm) | 中膜厚度/内径(%) |
正常组 | - | 19 | 32.8±8.9 | 185.4±50.9 | 18.1±4.3 |
模型组 | - | 16 | 64.4±14.8** | 118.3±27.6** | 53.4±13.4** |
奥美沙坦/吲达帕胺+左旋亚叶酸钙 | 2+0.25+0.02 | 18 | 39.9±6.9▲▲ | 165.7±27.8▲▲ | 24.6±6.1▲▲★ |
2+0.25+0.04 | 19 | 37.6±8.4▲▲ | 175.5±35.7▲▲ | 22.3±4.6▲▲★★ | |
奥美沙坦/吲达帕胺 | 2+0.25 | 17 | 45.6±8.7▲▲ | 153.9±41.4▲ | 30.1±5.8▲▲ |
左旋亚叶酸钙 | 0.04 | 17 | 61.4±16.8 | 125.9±38.7 | 49.4±12.6 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101657754A CN101199847B (zh) | 2006-11-11 | 2007-11-03 | At1受体拮抗剂/利尿剂/叶酸联用的药物组合物及其用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610146631 | 2006-11-11 | ||
CN200610146631.X | 2006-11-11 | ||
CN2007101657754A CN101199847B (zh) | 2006-11-11 | 2007-11-03 | At1受体拮抗剂/利尿剂/叶酸联用的药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101199847A true CN101199847A (zh) | 2008-06-18 |
CN101199847B CN101199847B (zh) | 2011-10-12 |
Family
ID=39515331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101657754A Active CN101199847B (zh) | 2006-11-11 | 2007-11-03 | At1受体拮抗剂/利尿剂/叶酸联用的药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101199847B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103721259A (zh) * | 2014-01-07 | 2014-04-16 | 深圳奥萨医药有限公司 | 血管紧张素ⅱ受体阻断剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物 |
CN106109470A (zh) * | 2016-06-13 | 2016-11-16 | 佛山市腾瑞医药科技有限公司 | 一种复方甲磺酸依普罗沙坦、氢氯噻嗪颗粒剂及其制法 |
CN116530469A (zh) * | 2023-07-06 | 2023-08-04 | 首都医科大学 | 腹主动脉瘤动物模型的制备方法与应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037692B (zh) * | 2015-04-27 | 2017-03-01 | 中国科学院化学研究所 | 聚噻吩及其制备方法与应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1199641C (zh) * | 2002-10-24 | 2005-05-04 | 王登之 | 一种用于治疗高血压的复方厄贝沙坦胶囊 |
CN1602960A (zh) * | 2004-07-23 | 2005-04-06 | 海南国栋药物研究所有限公司 | 一种防治心脑血管病及糖尿病等代谢综合症的复合制剂 |
CN1286844C (zh) * | 2004-07-28 | 2006-11-29 | 安徽省生物医学研究所 | 含有血管紧张素ⅱ受体拮抗剂和b族维生素的药物组合物 |
-
2007
- 2007-11-03 CN CN2007101657754A patent/CN101199847B/zh active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103721259A (zh) * | 2014-01-07 | 2014-04-16 | 深圳奥萨医药有限公司 | 血管紧张素ⅱ受体阻断剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物 |
CN106109470A (zh) * | 2016-06-13 | 2016-11-16 | 佛山市腾瑞医药科技有限公司 | 一种复方甲磺酸依普罗沙坦、氢氯噻嗪颗粒剂及其制法 |
CN116530469A (zh) * | 2023-07-06 | 2023-08-04 | 首都医科大学 | 腹主动脉瘤动物模型的制备方法与应用 |
CN116530469B (zh) * | 2023-07-06 | 2023-09-19 | 首都医科大学 | 腹主动脉瘤动物模型的制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101199847B (zh) | 2011-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101199848B (zh) | 钙通道阻滞剂/利尿剂/叶酸联用的药物组合物及其用途 | |
CN100551442C (zh) | 含有钙通道阻滞剂和b族维生素的药物组合物及其用途 | |
CN101199847B (zh) | At1受体拮抗剂/利尿剂/叶酸联用的药物组合物及其用途 | |
CN101406472A (zh) | 阿替洛尔/氨氯地平/叶酸类化合物的药物组合物及其用途 | |
CN101176788B (zh) | Ace抑制剂/利尿剂/叶酸联用的药物组合物及其用途 | |
CN103386130A (zh) | Ace抑制剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物及用途 | |
CN101590052A (zh) | 含有钙离子拮抗剂、他汀类降脂药和烟酸的药物组合物及其用途 | |
CN106924712A (zh) | 一种新的抗高血压复方缓释片剂及生产工艺 | |
CN106310278A (zh) | 一种含叶酸的多联降压药物组合物 | |
CN102370965A (zh) | 一种含有左旋氨氯地平药学上可接受的盐与培哚普利药学上可接受的盐的药物组合物 | |
CN104224788A (zh) | 吲哒帕胺和叶酸的药物组合物及其用途 | |
CN103272236B (zh) | 含有β-肾上腺素受体阻滞剂和B族维生素的药物组合物及其用途 | |
CN101590239B (zh) | 含有利尿剂、他汀和叶酸的药物组合物及其用途 | |
CN103230594A (zh) | α-葡萄糖苷酶抑制剂和B族维生素的药物组合物 | |
CN1969855B (zh) | 一种具有靶器官保护作用的药物组合物及其用途 | |
CN101590240B (zh) | 含血管紧张素ⅱ受体拮抗剂、他汀和叶酸的组合物及用途 | |
CN101590030A (zh) | 含有阿利吉仑、氢氯噻嗪和叶酸的药物组合物及其用途 | |
CN101590230A (zh) | 含有肾素抑制剂、利尿剂和叶酸的药物组合物及其用途 | |
CN101347434B (zh) | 含有肾素抑制剂与叶酸类化合物的药物组合物及其用途 | |
CN103721259A (zh) | 血管紧张素ⅱ受体阻断剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物 | |
CN101683526B (zh) | 含有血管紧张素ⅱ受体拮抗剂、b族维生素和银杏叶提取物的药物组合物 | |
CN101590232A (zh) | 血管紧张素转化酶抑制剂、他汀类降脂药和烟酸的药物组合物及其用途 | |
CN103861081A (zh) | 一种培哚普利氨氯地平片剂及其生产工艺 | |
CN102631357B (zh) | 一种缬沙坦与氢氯噻嗪药物组合物片剂及其制备方法 | |
CN110237258A (zh) | 用于治疗高血压的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Drug compound for AT1 receptor antagonist/diuretic/folate coupling and uses thereof Effective date of registration: 20130523 Granted publication date: 20111012 Pledgee: China Everbright Bank Shenzhen Bagualing branch Pledgor: Anhui Biological Medical Institute|SHENZHEN AUSA PHARMED Co.,Ltd. Registration number: 2013990000307 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160705 Granted publication date: 20111012 Pledgee: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgor: Anhui Biological Medical Institute|SHENZHEN AUSA PHARMED Co.,Ltd. Registration number: 2013990000307 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160705 Registration number: 2013990000307 Pledgee after: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgee before: China Everbright Bank Shenzhen Bagualing branch |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: Three, No. 16 biological incubator No. 518057, high tech Zone, central high tech Zone, Shenzhen, Guangdong, Nanshan District Co-patentee after: Anhui Biological Medical Institute Patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Address before: 518057, a bio incubator building in Nanshan District hi tech Zone, Guangdong, Shenzhen 1-301 Co-patentee before: Anhui Biological Medical Institute Patentee before: SHENZHEN AUSA PHARMED Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230712 Address after: 518057 High tech Zone, Nanshan District, Shenzhen City, Guangdong Province, China. Phase III of the Biological Incubator, No. 16 High tech Middle Road, Building 2, 1st and 2nd floors, 2nd and 3rd floors, east side of the 1st and 3rd floors of Building 2 Patentee after: SHENZHEN AUSA PHARMACEUTICAL Co.,Ltd. Patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee after: Anhui Biological Medical Institute Address before: 518057 Phase III Biological Incubator No. 16, Zhongxin Zhongdao, Nanshan High-tech Zone, Shenzhen City, Guangdong Province Patentee before: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee before: Anhui Biological Medical Institute |